ARCHIVES

Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

National Cancer Policy Board calls for public-private partnership for R&D in pediatric cancer drugs.

April 22, 2005

Health Reform Bill Contains Unpleasant Surprises For Drug Manufacturers

November 5, 1993

Radiation To Stem Cell Niche Improved PFS In Glioblastoma

August 27, 2010

AACR Receives Record Number of Abstracts

January 27, 1989

Cancer Policy: President’s Cancer Panel Issues Statement On National Cancer Program

September 17, 1999

In Brief: U – South Western Wins BMS Grant; ONS Gets $1.6 M; Unilever Chair In Diet Formed At CINJ

May 7, 1999